Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 5;3(1):137.
doi: 10.1038/s43856-023-00366-x.

Participant characteristics in the prevention of gestational diabetes as evidence for precision medicine: a systematic review and meta-analysis

Collaborators, Affiliations

Participant characteristics in the prevention of gestational diabetes as evidence for precision medicine: a systematic review and meta-analysis

Siew Lim et al. Commun Med (Lond). .

Abstract

Background: Precision prevention involves using the unique characteristics of a particular group to determine their responses to preventive interventions. This study aimed to systematically evaluate the participant characteristics associated with responses to interventions in gestational diabetes mellitus (GDM) prevention.

Methods: We searched MEDLINE, EMBASE, and Pubmed to identify lifestyle (diet, physical activity, or both), metformin, myoinositol/inositol and probiotics interventions of GDM prevention published up to May 24, 2022.

Results: From 10347 studies, 116 studies (n = 40940 women) are included. Physical activity results in greater GDM reduction in participants with a normal body mass index (BMI) at baseline compared to obese BMI (risk ratio, 95% confidence interval: 0.06 [0.03, 0.14] vs 0.68 [0.26, 1.60]). Combined diet and physical activity interventions result in greater GDM reduction in participants without polycystic ovary syndrome (PCOS) than those with PCOS (0.62 [0.47, 0.82] vs 1.12 [0.78-1.61]) and in those without a history of GDM than those with unspecified GDM history (0.62 [0.47, 0.81] vs 0.85 [0.76, 0.95]). Metformin interventions are more effective in participants with PCOS than those with unspecified status (0.38 [0.19, 0.74] vs 0.59 [0.25, 1.43]), or when commenced preconception than during pregnancy (0.21 [0.11, 0.40] vs 1.15 [0.86-1.55]). Parity, history of having a large-for-gestational-age infant or family history of diabetes have no effect on intervention responses.

Conclusions: GDM prevention through metformin or lifestyle differs according to some individual characteristics. Future research should include trials commencing preconception and provide results disaggregated by a priori defined participant characteristics including social and environmental factors, clinical traits, and other novel risk factors to predict GDM prevention through interventions.

Plain language summary

An individual’s characteristics, such as medical, biochemical, social, and behavioural may affect their response to interventions aimed at preventing gestational diabetes, which occurs during pregnancy. Here, we evaluated the published literature on interventions such as diet, lifestyle, drug treatment and nutritional supplement and looked at which individual participant characteristics were associated with response to these interventions. Certain participant characteristics were associated with greater prevention of gestational diabetes through particular treatments. Some interventions were more effective when started prior to conception. Future studies should consider individual characteristics when assessing the effects of preventative measures.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. PRISMA flow diagram.
Flowchart demonstrating the process of the identifying the papers included in this review. This maps out the number of records identified, included and excluded at each stage of assessment. Reasons for full text exclusions are provided.

Update of

Similar articles

Cited by

  • Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.
    Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, Duan D, Felton JL, Francis EC, Gillard P, Gingras V, Gaillard R, Haider E, Hughes A, Ikle JM, Jacobsen LM, Kahkoska AR, Kettunen JLT, Kreienkamp RJ, Lim LL, Männistö JME, Massey R, Mclennan NM, Miller RG, Morieri ML, Most J, Naylor RN, Ozkan B, Patel KA, Pilla SJ, Prystupa K, Raghavan S, Rooney MR, Schön M, Semnani-Azad Z, Sevilla-Gonzalez M, Svalastoga P, Takele WW, Tam CH, Thuesen ACB, Tosur M, Wallace AS, Wang CC, Wong JJ, Yamamoto JM, Young K, Amouyal C, Andersen MK, Bonham MP, Chen M, Cheng F, Chikowore T, Chivers SC, Clemmensen C, Dabelea D, Dawed AY, Deutsch AJ, Dickens LT, DiMeglio LA, Dudenhöffer-Pfeifer M, Evans-Molina C, Fernández-Balsells MM, Fitipaldi H, Fitzpatrick SL, Gitelman SE, Goodarzi MO, Grieger JA, Guasch-Ferré M, Habibi N, Hansen T, Huang C, Harris-Kawano A, Ismail HM, Hoag B, Johnson RK, Jones AG, Koivula RW, Leong A, Leung GKW, Libman IM, Liu K, Long SA, Lowe WL Jr, Morton RW, Motala AA, Onengut-Gumuscu S, Pankow JS, Pathirana M, Pazmino S, Perez D, Petrie JR, Powe CE, Quinteros A, Jain R, Ray D, Ried-Larsen M, Saeed Z, Santhakumar V, Kanbour S, Sarkar … See abstract for full author list ➔ Tobias DK, et al. Nat Med. 2023 Oct;29(10):2438-2457. doi: 10.1038/s41591-023-02502-5. Epub 2023 Oct 5. Nat Med. 2023. PMID: 37794253 Free PMC article. Review.
  • Integrated single-cell and spatial transcriptomics reveal microenvironment disruptions by androgen in mouse ovary.
    Luo M, Yang X, Zhou M, Zhang J, Yu B, Lian H, Ye J. Luo M, et al. iScience. 2024 Sep 24;27(10):111028. doi: 10.1016/j.isci.2024.111028. eCollection 2024 Oct 18. iScience. 2024. PMID: 39429789 Free PMC article.
  • Nutrients as Risk Factors and Treatments for Gestational Diabetes.
    Petry CJ. Petry CJ. Nutrients. 2023 Nov 8;15(22):4716. doi: 10.3390/nu15224716. Nutrients. 2023. PMID: 38004110 Free PMC article.
  • Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist.
    Lim SS, Semnani-Azad Z, Morieri ML, Ng AH, Ahmad A, Fitipaldi H, Boyle J, Collin C, Dennis JM, Langenberg C, Loos RJF, Morrison M, Ramsay M, Sanyal AJ, Sattar N, Hivert MF, Gomez MF, Merino J, Tobias DK, Trenell MI, Rich SS, Sargent JL, Franks PW. Lim SS, et al. Nat Med. 2024 Jul;30(7):1874-1881. doi: 10.1038/s41591-024-03033-3. Epub 2024 Jul 19. Nat Med. 2024. PMID: 39030405 Review.
  • A narrative review of metformin in pregnancy: Navigating benefit and uncertainty.
    McEvoy RP, Newman C, Egan AM, Dunne FP. McEvoy RP, et al. Diabetes Obes Metab. 2025 Jun;27 Suppl 3(Suppl 3):16-30. doi: 10.1111/dom.16361. Epub 2025 Apr 2. Diabetes Obes Metab. 2025. PMID: 40171857 Free PMC article. Review.

References

    1. Freinkel N. Banting Lecture 1980. Of pregnancy and progeny. Diabetes. 1980;29:1023–1035. doi: 10.2337/diab.29.12.1023. - DOI - PubMed
    1. Zhang Y, et al. Factors associated with gestational diabetes mellitus: a meta-analysis. J. Diab. Res. 2021;2021:6692695. - PMC - PubMed
    1. Habibi N, et al. Maternal metabolic factors and the association with gestational diabetes: A systematic review and meta-analysis. Diabetes Metab. Res. Rev. 2022;38:e3532. doi: 10.1002/dmrr.3532. - DOI - PMC - PubMed
    1. Sweeting A, Wong J, Murphy HR, Ross GP. A clinical update on gestational diabetes mellitus. Endocr. Rev. 2022;43:763–793. doi: 10.1210/endrev/bnac003. - DOI - PMC - PubMed
    1. Lowe WL, Jr., et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA. 2018;320:1005–1016,. doi: 10.1001/jama.2018.11628. - DOI - PMC - PubMed